EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Development of Novel ROCK Inhibitors via 3D-QSAR and Molecular Docking Studies: A Framework for Multi-Target Drug Design

Milan Beljkas, Milos Petkovic iD, Ana Vuletic, Ana Djuric iD, Juan Francisco Santibanez iD, Tatjana Srdic-Rajic iD, Katarina Nikolic iD, Slavica Oljacic iD

Pharmaceutics · 26.09.2024 · 16 (10) · 1250

DOI: 10.3390/pharmaceutics16101250 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Pharmaceutics, online erschienen am 26.09.2024. Verfasst von Milan Beljkas und 7 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pharmaceutical Chemistry, Faculty of Pharmacy, University of Belgrade, Vojvode Stepe 450, 11221 Belgrade, Serbia. Die Arbeit wurde bisher 11-mal zitiert (Crossref) und nennt 59 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Ministry of Science, Technological Development and Innovation, Republic of Serbia, Ministry of Science, Technological Development and Innovation, Republic of Serbia, through Grant Agreement with University of Belgrade (Faculty of Pharmacy), Institute for Oncology and Radiology of Serbia.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background/Objectives: Alterations in the actin cytoskeleton correlates to tumor progression and affect critical cellular processes such as adhesion, migration and invasion. Rho-associated coiled-coil-containing protein kinases (ROCK1 and ROCK2), important regulators of the actin cytoskeleton, are frequently overexpressed in various malignancies. The aim of this study was therefore to identify the key structural features of ROCK1/ROCK2 inhibitors using computer-aided drug design (CADD) approaches. In addition, new developed ROCK inhibitors provided a significant framework for the development of multitarget therapeutics—ROCK/HDAC (histone deacetylases) multitarget inhibitors.

Methods

3D-QSAR (Quantitative structure-activity relationship study) and molecular docking study were employed in order to identify key structural features that positively correlate with ROCK inhibition. MDA-MB-231, HCC1937, Panc-1 and Mia PaCa-2 cells were used for evaluation of anticancer properties of synthesized compounds.

Results

C-19 showed potent anti-cancer properties, especially enhancement of apoptosis and cell cycle modulation in pancreatic cancer cell lines. In addition, C-19 and C-22 showed potent anti-migratory and anti-invasive effects comparable to the well-known ROCK inhibitor fasudil.

Conclusions

In light of the results of this study, we propose a novel multi-target approach focusing on developing dual HDAC/ROCK inhibitors based on the structure of both C-19 and C-22, exploiting the synergistic potential of these two signaling pathways to improve therapeutic efficacy in metastatic tumors. Our results emphasize the potential of multi-target ROCK inhibitors as a basis for future cancer therapies.

Schlagwörter

Stichwörter der Autor:innen

3D-QSARRho-associated protein kinasesantineoplastic agentsbreast cancermolecular modelingmultitarget-directed ligandspancreatic ductal adenocarcinomarational drug design

Autor:innen und Institutionen

  • Department of Pharmaceutical Chemistry, Faculty of Pharmacy, University of Belgrade, Vojvode Stepe 450, 11221 Belgrade, Serbia.
  • Department of Organic Chemistry, Faculty of Pharmacy, University of Belgrade, Vojvode Stepe 450, 11221 Belgrade, Serbia.
  • Department of Experimental Oncology, Institute for Oncology and Radiology of Serbia, Pasterova 14, 11000 Belgrade, Serbia.
  • Group for Molecular Oncology, Institute for Medical Research, National Institute of the Republic of Serbia, University of Belgrade, Dr. Subotica 4, 11129 Belgrade, Serbia.

ORCID-Profile: Milos Petkovic, Ana Djuric, Juan Francisco Santibanez, Tatjana Srdic-Rajic, Katarina Nikolic, Slavica Oljacic

Förderung

  • Ministry of Science, Technological Development and Innovation, Republic of Serbia
  • Ministry of Science, Technological Development and Innovation, Republic of Serbia, through Grant Agreement with University of Belgrade (Faculty of Pharmacy)
  • Institute for Oncology and Radiology of Serbia
  • Institute for Medical Research

Zitieren

APA

Beljkas, M., Petkovic, M., Vuletic, A., Djuric, A., Santibanez, J. F., Srdic-Rajic, T., Nikolic, K., & Oljacic, S. (2024). Development of Novel ROCK Inhibitors via 3D-QSAR and Molecular Docking Studies: A Framework for Multi-Target Drug Design. Pharmaceutics, 16(10), 1250. https://doi.org/10.3390/pharmaceutics16101250

Vancouver

Beljkas M, Petkovic M, Vuletic A, Djuric A, Santibanez JF, Srdic-Rajic T, et al. Development of Novel ROCK Inhibitors via 3D-QSAR and Molecular Docking Studies: A Framework for Multi-Target Drug Design. Pharmaceutics. 2024;16(10):1250. doi:10.3390/pharmaceutics16101250

BibTeX
@article{Beljkas2024,
  author = {Beljkas, Milan and Petkovic, Milos and Vuletic, Ana and Djuric, Ana and Santibanez, Juan Francisco and Srdic-Rajic, Tatjana and Nikolic, Katarina and Oljacic, Slavica},
  title = {Development of Novel ROCK Inhibitors via 3D-QSAR and Molecular Docking Studies: A Framework for Multi-Target Drug Design},
  journal = {Pharmaceutics},
  year = {2024},
  volume = {16},
  number = {10},
  pages = {1250},
  doi = {10.3390/pharmaceutics16101250}
}
Kostenlos starten →